AstraZeneca's Farxiga gets FDA approval to reduce risk of death due to heart failure
Leon Neal

The U.S. Food and Drug Administration (FDA) approved the expanded use of AstraZeneca's (NASDAQ:AZN) Farxiga to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF.
Farxiga was previously approved in the U.S. to treat adults with HF with reduced ejection fraction (HFrEF).

The current approval was backed by data from a phase 3 trial called DELIVER.
Farxiga (dapagliflozin) is also approved in the U.S. and over 100 countries to treat patients with type-2 diabetes (T2D), HFrEF and chronic kidney disease (CKD), among other things, according to the British pharma giant.